0
0
The United Kingdom has taken a significant step toward combating antibiotic-resistant infections with the release of its first official guidance for the safe development and use of phage therapies. Published by the Medicines and Healthcare products Regulatory Agency (MHRA), this guidance aims to streamline the path for researchers and companies working on phage-based medicines, ensuring these innovative treatments meet stringent safety, quality, and efficacy standards before reaching patients.
Phage therapies utilize bacteriophages—viruses that specifically target and destroy harmful bacteria without affecting human cells. With antibiotic resistance on the rise and over 60,000 serious cases estimated annually in the U.K., the need for alternative treatments has become urgent. While some patients have already received phage therapy under compassionate use programs, often with imported products, no phage medicines are currently licensed for use in the U.K.
Lawrence Tallon, chief executive of MHRA, emphasized the importance of the new guidance:
“Some infections are becoming harder to treat when antibiotics are ineffective against them, and patients urgently need new options. Phage therapy is one of several promising approaches. This guidance brings together relevant standards to provide clarity for researchers and companies, so they can develop these treatments safely and bring them to the people who need them.”
Key Features of the Guidance
-
Comprehensive Coverage: The guidance addresses both standardized phage products for common infections and personalized therapies tailored to individuals with rare or highly resistant infections.
-
Patient Access: It clarifies how patients might access phage treatments when standard antibiotics fail or cannot be used due to allergies.
-
Regulatory Clarity: The document outlines how existing U.K. and international regulatory frameworks apply to phage therapies, from early research to clinical use.
-
Practical Advice: It details requirements for clinical trials, market authorization, manufacturing standards (including Good Manufacturing Practice), and the use of unlicensed treatments under clinician responsibility.
-
Support for Innovators: Companies can seek scientific advice from the MHRA at any stage of development, helping them navigate the regulatory landscape more efficiently.
Frederique Vieville, Phage ACT Lead at the BEAM Alliance and CEO of 5QBD, highlighted the importance of regulatory clarity:
“Clarity about the pathway—tailored to the unique characteristics of phages—is vital to help meet quality, non-clinical, and clinical requirements, and ultimately bring phage-based treatments to patients more efficiently.”
Jason Clark, PhD, director and CSO at NexaBiome, added:
“This new guidance from the MHRA is incredibly forward-thinking and puts the U.K. in pole position to fully realize the healthcare and commercial benefits of this exciting technology.”
A Step Forward in the Fight Against Antibiotic Resistance
As difficult-to-treat infections continue to rise globally, the MHRA’s forward-thinking approach positions the U.K. as a leader in the development and regulation of phage therapies. By providing clear, practical, and unified regulatory advice, the guidance is expected to accelerate the availability of these promising treatments for patients in need.
Disclaimer:
This article is based on information published by GEN (Genetic Engineering & Biotechnology News) and the MHRA. The content is intended for informational purposes only and does not constitute medical or regulatory advice. For full details, refer to the official MHRA guidance document.
